ОбзорГрафикПрофильОсновная статистикаФинансовые показателиТехническийНовости
Деривативы
TraderScreen

Vertex Pharmaceuticals Inc/  US92532F1003  /

NASDAQ
20.12.2024  22:00:00 Изменение +0.6300 Объем сделки Бид1:59:55 Предложение1:59:55 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
397.2700USD +0.16% 6.2 млн
Оборот: 1.75 млрд		 394.0000Величина цены спроса: 200 395.3500Величина цены предложения: 200 102.31 млрдUSD - 28.28
GlobeNewswire 13.08 Entrada Therapeutics Reports Second Quarter 2024 Financial Results
GlobeNewswire 09.08 ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
GlobeNewswire 07.08 Editas Medicine Announces Second Quarter 2024 Results and Business Updates
GlobeNewswire 05.08 Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
GlobeNewswire 05.08 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Newsfile Corp 17.07 Analysts Hunt for Undervalued Biotech Stocks
Newsfile Corp 11.07 Biopharma Stocks Transformative Innovation for the Future of Health
GlobeNewswire 09.07 Payscale Expands Data & Technology Resources, Powering Decision-Focused Compensation Management
GlobeNewswire 09.07 Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
GlobeNewswire 28.06 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...
GlobeNewswire 10.06 Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as C...
GlobeNewswire 29.05 CRISPR Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire 23.05 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 15.05 Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 09.05 CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire 08.05 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire 08.05 CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire 08.05 Editas Medicine Announces First Quarter 2024 Results and Business Updates
GlobeNewswire 07.05 Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 30.04 American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire 27.04 SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire 25.04 American Kidney Fund Launches National Kidney Health Equity Media Campaign
GlobeNewswire 22.04 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire 22.04 CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire 22.04 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN